



**Grŵp Strategaeth Meddyginiaethau Cymru Gyfan**  
**All Wales Medicines Strategy Group**

**Meeting to commence at 9.30 am on Tuesday 8<sup>th</sup> March 2022  
(via Zoom)**

**AGENDA**

**Enclosure**

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of the previous meeting** 1/AWMSG/0322
5. **Chairman's report**
6. **National Prescribing Indicators Quarterly Report: Analysis of data to September 2021** 2/AWMSG/0322
7. **NHS Wales inhaler carbon footprint report** 3/AWMSG/0322
8. **Appraisal 1 – Paediatric Licence Extension** 4/AWMSG/0322  
**Adalimumab (Humira®)** for treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies Appendices

**To protect commercial confidentiality the following appraisal will be held in private and all observers will be asked to leave the meeting**

9. **Appraisal 2 – Full Submission (WPAS) - Postponed** 5/AWMSG/0322  
**Hydrocortisone MR (Efmody®)** for treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults Appendices

**The outcome of all appraisals will be uploaded to the AWMSG website after the meeting.**

**Date and time of next meeting: Wednesday 27<sup>th</sup> April 2022 at 9:30 am**